Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study - ScienceDirect
2011 Prostate Cancer Highlights, Prostate Cancer Research Program, Congressionally Directed Medical Research Programs
Abiraterone acetate for the treatment of castrate-refractory prostate cancer | Aging Health
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born - Michael T. Schweizer, Emmanuel S. Antonarakis, 2012
Cancers | Free Full-Text | Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer | SpringerLink
Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma Nandha R - J Postgrad Med
AusPAR Attachment 1: Product Information for Zytiga (abiraterone acetate)
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses | Arteriosclerosis, Thrombosis, and Vascular Biology
Zytiga (Abiraterone J&J) for Treatment of Prostate Cancer (mCRPC) - Prostate Cancer Specialists in NYC
pipeline -
Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
Abiraterone Acetate API Manufacturer and Supplier | CAS 154229-18-2 - Dr. Reddy's
AUA 2012 - mCRPC in focus: Androgen biosynthesis inhibition and metastatic castration-resistant prostate cancer, clinical insights from the Clinical Industry Theater presentation by Judd Moul, MD
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial | BMC Cancer | Full Text
Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Abiraterone acetate in the treatment of prostate cancer - ScienceDirect
Abiraterone acetate in the treatment of prostate cancer - ScienceDirect
Oncology
The accidental discovery of the world's most expensive prebiotic? | Microbiology Community
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer - Qin - 2018 - Clinical Pharmacology & Therapeutics - Wiley Online Library
